Regular blood tests are key. Monitor complete blood counts (CBCs), including white blood cell (WBC), red blood cell (RBC), and platelet counts, every 2-4 weeks initially, then monthly once stable. Adjust dosage based on these results.
Monitoring Liver Function
Liver function tests (LFTs), specifically ALT and AST levels, should be checked before starting treatment and then every 2-4 weeks for the first few months. Significant elevations may necessitate dose reduction or treatment discontinuation.
Dosage Adjustment Guidelines
- WBC Count: Reduce the dose if the WBC count falls below 3,000/µL. Consider temporarily suspending treatment if it drops below 2,000/µL. Resume at a lower dose once the count recovers. Platelet Count: Reduce the dose if the platelet count falls below 50,000/µL. Hold the medication if it drops below 25,000/µL. Close monitoring is crucial. Thiopurine Methyltransferase (TPMT) Testing: Pre-treatment TPMT testing helps predict metabolism. Individuals with low TPMT activity require lower doses to prevent toxicity. Liver Function: Reduce or discontinue mercaptopurine if ALT or AST levels exceed three times the upper limit of normal.
Additional Considerations
Individual responses vary. Adjustments might be needed based on clinical response and tolerability. Close collaboration between the patient and healthcare provider is essential throughout treatment. Report any symptoms of infection, unusual bruising, bleeding, or jaundice immediately.
Dose Escalation
If the patient tolerates the initial dose well and shows clinical improvement without blood count suppression, gradual dose escalation may be considered, guided by blood test results and clinical response. Typically this involves increases of 10-25mg every 2-4 weeks, while closely observing blood counts.
